Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: StemRIM

Market Cap 20.12B 125M 109M 100M 94.49M 176M 11.76B 178M 1.19B 462M 5.79B 468M 458M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 13.13B 81.36M 71.02M 65.41M 61.64M 115M 7.67B 116M 774M 302M 3.78B 306M 299M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
47.55%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 65 30/09/2022
Chief Executive Officer 58 24/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 65 31/01/2007
Director/Board Member 58 28/02/2019
Director/Board Member 54 30/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 117M
+0.33%+1.38%+19.86%-22.11% 61.85B
-1.27%-5.75%+57.57%+190.51% 55.69B
+4.38%+43.00%+43.00%+43.00% 41.88B
+1.21%+4.98%-54.83%-61.10% 36.15B
-1.05%+1.20%+55.33%-33.92% 29.33B
+3.50%+39.07%+150.33%-50.31% 24.52B
-0.78%-6.80%+42.74%+55.34% 19.78B
+1.74%+2.42%-1.23%+107.49% 16.61B
-0.05%+1.20%+56.88%+94.95% 16.2B
Average +0.45%+5.09%+41.07%+35.98% 33.56B
Weighted average by Cap. +0.52%+4.16%+37.45%+36.50%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.53M -10.94M -10.08M -9.5M -17.71M -1.18B -17.87M -119M -46.47M -582M -47.06M -46.05M -1.93B -11.96M -10.44M -9.61M -9.06M -16.89M -1.13B -17.05M -114M -44.33M -555M -44.9M -43.93M
Net Debt -8.41B -52.13M -45.5M -41.91M -39.49M -73.65M -4.92B -74.32M -496M -193M -2.42B -196M -192M -6.99B -43.35M -37.84M -34.85M -32.84M -61.25M -4.09B -61.81M -412M -161M -2.01B -163M -159M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
45
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!